NDC product
Buprenorphine
NDC 0093-3659 · Teva Pharmaceuticals USA, Inc.
Key facts
| Product NDC | 0093-3659 |
|---|---|
| Proprietary name | Buprenorphine |
| Nonproprietary name | Buprenorphine |
| Substances | BUPRENORPHINE |
| Dosage form | PATCH, EXTENDED RELEASE |
| Route | TRANSDERMAL |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA204937 |
| DEA schedule | CIII |
| Pharmacologic classes | Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA] |
| Marketing start | Nov 26, 2018 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: